Microsoft Form Alliance To Accelerate Pace of Drug Development
A leading global biopharmaceutical services organization, PAREXEL Crop, has now teamed up with Microsoft- announcing a technology development alliance aimed at driving innovation across the life sciences industry with technology powered by Microsoft Azure.
The collaboration aims to help the industry accelerate drug development and will combine Microsoft’s global cloud infrastructure, intelligent services, and research and development capabilities with PAREXEL’s global presence and its clinical and regulatory technology domain expertise.
Under the terms of the alliance, Microsoft Azure becomes Parexel’s preferred cloud platform, similar to deals the Redmond, Wash. software giant has struck with Adobe and SAP SuccessFactors. Microsoft and Parexel are also collaborating on cloud services and technologies that help life sciences organizations conduct clinical research and expand market access.
Microsoft Azure is an open, flexible, enterprise-grade cloud computing platform and set of services. Businesses looking to digitally transform with Microsoft Azure benefit from Microsoft’s more than $1 billion investment in security research per year, an industry-leading cloud regulatory compliance portfolio, and global scale that includes 42 datacenter regions announced, more than any other cloud provider.
PAREXEL Informatics provides innovative technology solutions to help optimize patient engagement, clinical and regulato
ry processes. The integrated solutions are designed to improve how biopharmaceutical companies perform clinical trials, control, and share data, track and report patient outcomes, manage regulatory information worldwide, and capture real-world evidence for payers.“Drug development is becoming more complex, while innovations including social media, analytics, mobile technology and the Internet of Things are enabling a more patient-centric approach,” Xavier Flinois, president of Parexel Informatics, the company’s technology subsidiary, said in a statement. “In combination, Microsoft’s leading innovations and commitment to security and regulatory compliance, along with Parexel’s industry expertise, will allow us to bring accelerated drug delivery timelines and improved patient engagement to the industry.”
“We’re delighted to be partnering with Parexel to unlock the opportunities of digital transformation for the life sciences industry,” said Peggy Johnson, executive vice president, business development at Microsoft. “By combining the global scale and intelligent capabilities of Microsoft Azure with Parexel’s biopharmaceutical expertise, together we will help life science companies to accelerate the drug development and commercialization process, all built on a foundation of trust, security, and compliance with the Microsoft cloud.”